Orgenesis (Orgenesis) Institutional Ownership : 5.12% (As of Apr. 26, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Orgenesis Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Orgenesis's institutional ownership is 5.12%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Orgenesis's Insider Ownership is 6.67%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Orgenesis's Float Percentage Of Total Shares Outstanding is 98.12%.

Orgenesis Institutional Ownership Historical Data

The historical data trend for Orgenesis's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Institutional Ownership Chart

Orgenesis Historical Data

The historical data trend for Orgenesis can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	8.10	8.09	7.52	7.50	5.72	5.50	5.49	5.49	5.49	5.12

Orgenesis Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Orgenesis (Orgenesis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (NAS:ORGS) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

45O:Germany

Address

20271 Goldenrod Lane, Germantown, MD, USA, 20876

Website

https://www.orgenesis.com

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Executives

Elliot Maltz	officer: Chief Financial Officer	C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Jacob Safier	10 percent owner	C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Efrat Assa Kunik	officer: Chief Development Officer	C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky	director	JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips	director	C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber	officer: Chief Scientific Officer	17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin	director	7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler	director	4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan	officer: CEO	20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles	10 percent owner	AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger	10 percent owner	DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus	10 percent owner	ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus	10 percent owner	ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret	officer: See Remarks	48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda	director	2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452